Hong Kong Attraction For Clinical Trials Hit By Two-Year Licensing Limit
This article was originally published in PharmAsia News
Executive Summary
Hong Kong's clinical-trial regulations, which allow a license for only two years, have led the city to lose its status as a leading hub for trials to rivals such as South Korea and Taiwan.